Skip to Main content Skip to Navigation
Journal articles

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours

David Sefrioui 1 France Blanchard 2 Emmanuel Toure 1 Paul Basile 1 Ludivine Beaussire 3 Claire Dolfus 3 Anne Perdrix 3 Marianne Paresy 2 Michel Antonietti 4 Isabelle Iwanicki-Caron 4 Raied Alhameedi 4 Stéphane Lecleire 4 Alice Gangloff 4 Lilian Schwarz 5 Florian Clatot 6, 1 Jean-Jacques Tuech 5 Thierry Frébourg 1, 2 Fabrice Jardin 7 Jean-Christophe Sabourin 2, 1 Nasrin Sarafan-Vasseur 1 Pierre Michel 8 Frédéric Di Fiore 4, 1
1 GPMCND - Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques
2 CHU Rouen
3 GMFC - Génétique du cancer et des maladies neuropsychiatriques
4 Service d'Hépato-Gastroentérologie [CHU Rouen]
5 Service de chirurgie digestive [CHU Rouen]
6 Service d'Oncologie Médicale
7 Synergie Lyon Cancer-Platform of Bioinformatics-Gilles Thomas
UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
8 GREAM - Groupe de recherches expérimentales sur l'acte musical - [LabEx]
Abstract : Background: The direct comparison of CA19.9, circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) using endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has never been performed for the diagnosis of solid pancreatic tumours (SPTs). Methods: We included 68 patients with a SPT referred for EUS-FNA. CTCs were analysed using size-based platform and ctDNA using digital PCR. The sensitivity, specificity, negative and positive predictive values were evaluated for each marker and their combination. Results: SPTs corresponded to 58 malignant tumours (52 pancreatic adenocarcinoma (PA) and 6 others) and 10 benign lesions. The sensitivity and specificity for PA diagnosis were 73% and 88% for EUS-FNA, 67% and 80% for CTC, 65% and 75% for ctDNA and 79% and 93% for CA19.9, respectively. The positivity of at least 2 markers was associated with a sensitivity and specificity of 78% and 91%, respectively. CtDNA was the only marker associated with overall survival (median 5.2 months for ctDNA þ vs 11.0 months for ctDNA , P 1⁄4 0.01). Conclusions: CA19.9 alone and in combination with ctDNA and/or CTC analysis may represent an efficient method for diagnosing PA in patients with SPTs. Further studies including a larger cohort of patients with both malignant and benign lesions will be necessary to confirm these promising results.
Keywords : CA19.9 circulating tumour DNA solid pancreatic tumours circulating tumour cells endoscopic ultrasound-guided fine needle aspiration pancreatic adenocarcinoma
Document type :
Journal articles
Complete list of metadatas

Cited literature [47 references]  Display  Hide  Download
https://hal-normandie-univ.archives-ouvertes.fr/hal-02377819
Contributor : David Sefrioui <>
Submitted on : Sunday, November 24, 2019 - 2:32:40 PM
Last modification on : Tuesday, October 20, 2020 - 10:48:36 AM
Long-term archiving on: : Tuesday, February 25, 2020 - 1:26:40 PM

File

Vignette du document
Sefrioui BJC 2017.pdf
Files produced by the author(s)

Identifiers

Collections

COMUE-NORMANDIE | FNCLCC | BECQUEREL | UNIV-LYON1 | SITE-ALSACE | UNIROUEN | GPMCND | CRCL | CNRS | UDL

Citation

David Sefrioui, France Blanchard, Emmanuel Toure, Paul Basile, Ludivine Beaussire, et al.. Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. British Journal of Cancer, Cancer Research UK, 2017, 117, pp.1017-1025. ⟨10.1038/bjc.2017.250⟩. ⟨hal-02377819⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

67

Files downloads

107